

1 **Title: Short-Term Immune Response After Inactivated SARS-CoV-2 (CoronaVac®, Sinovac)**
2 **And ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) Vaccinations in Thai Health Care**
3 **Workers**

4 Watsamon Jantarabenjakul, MD, PhD^{1,2,3}, Napaporn Chantasrisawad, MD^{1,2,3}, Thanyawee Puthanakit,
5 MD^{2,3}, Supaporn Wacharapluesadee, PhD⁴, Nattiya Hirankarn MD, PhD⁵, Vichaya Ruenjaiman, PhD⁵,
6 Leilani Paitoonpong, MD^{1,6}, Gompol Suwanpimolkul, MD^{1,6}, Pattama Torvorapanit, MD¹, Rakchanok
7 Pradit, MSN¹, Jiratchaya Sophonphan⁷, and Opass Putcharoen, MD^{1,6}

8 1. Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial
9 Hospital, Bangkok, Thailand

10 2. Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

11 3. Center of Excellence in Pediatric Infectious Diseases and Vaccines, Faculty of Medicine,
12 Chulalongkorn University, Bangkok, Thailand

13 4. King Chulalongkorn Memorial Hospital, Bangkok, Thailand

14 5. Center of Excellence in Immunology and Immune-Mediated Diseases, Department of
15 Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

16 6. Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

17 7. The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross
18 AIDS Research Centre, Bangkok, Thailand

19 **Short Running Title:** Immune response after COVID-19 vaccination

20 **Corresponding author:** Opass Putcharoen, MD

21 Postal Address: Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn
22 Memorial Hospital, Bangkok, Thailand, 10330

23 Email: Opass.p@chula.ac.th, Work telephone: 02-256-4930

24 Clinical trial registration number: TCTR20210325003

25 **250 for Abstract, 3362 for Text, 21 references, 3 tables, 3 figures and 4 supplementary tables**

26 **Short-Term Immune Response After Inactivated SARS-CoV-2 (CoronaVac®, Sinovac) And**
27 **ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) Vaccinations in Thai Health Care**
28 **Workers**

29 **Abstract**

30 **Background:** Inactivated SARS-CoV-2 (CoronaVac®, Sinovac, or SV) and ChAdOx1 nCoV-19
31 (Vaxzevria®, Oxford-Astra Zeneca, or AZ) vaccines have been administered to the health care workers
32 (HCWs) in Thailand.

33 **Objective:** To determine the short-term immune response after the SV and AZ vaccinations in HCWs.

34 **Methods:** In this prospective cohort study, HCWs who completed a 2-dose regimen of the SV or AZ
35 were included. Immune response was evaluated by surrogate viral neutralization test (sVNT) and anti-
36 SARS-CoV-2 total antibody. Blood samples were analyzed at 4 and 12 weeks after the complete SV
37 vaccination and at 4 weeks after each dose of the AZ vaccination. The primary outcome was the
38 seroconversion rate at 4-weeks after complete immunization.

39 **Results:** Overall, 185 HCWs with a median (IQR) age of 40.5(30.3-55.8) years (94 HCWs in the SV
40 group and 91 in the AZ group) were included. At 4 weeks after completing the SV vaccination, 60.6%
41 (95%CI:50.0-70.6%) had seroconversion evaluated by sVNT($\geq 68\%$ inhibition), comparable to the
42 patients recovered from mild COVID-19 infection(69.0%), with a rapid reduction to
43 12.2%(95%CI:6.3-20.8) at 12 weeks. In contrast, 85.7%(95%CI:76.8-92.2%) HCWs who completed
44 the second dose of the AZ for 4 weeks had seroconversion, comparable to the COVID-19 pneumonia
45 patients(92.5%). When using the anti-SAR-CoV-2 total antibody level(≥ 132 U/ml) criteria, only
46 71.3% HCWs in the SV group had seroconversion, compared to 100% in the AZ group.

47 **Conclusion:** A rapid decline of short-term immune response in the HCWs after the SV vaccination
48 indicates the need for a vaccine booster, particularly during the ongoing spreading of the SAR-CoV-2
49 variants of concern.

50 **Keywords:** SARS-CoV-2 vaccine, COVID-19 vaccine, Surrogate viral neutralizing antibody titer,
51 Anti-SARS-CoV-2 total antibody, Health care workers, Inactivated SARS-CoV-2 vaccine

52 **Introduction**

53 With efforts to create immunity against the global spreading of severe acute respiratory
54 syndrome coronavirus 2 (SARS-CoV-2) infection or Coronavirus diseases 2019 (COVID-19), several
55 SARS-CoV-2 vaccines have been developed and widely distributed. In Thailand, inactivated SARS-
56 CoV-2 (CoronaVac®, Sinovac, or SV) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca, or
57 AZ) vaccines have been administered to the front-line health care workers (HCWs) since March 2021.
58 While the SV is an inactivated whole-virion SARS-CoV-2 vaccine, the AZ is a replication-deficient
59 adenoviral vector vaccine.^{1,2} Therefore, the immunological mechanisms of vaccine-induced protection
60 against SARS-CoV-2 in humans were different.³

61 In general, natural infection creates a protective immunity against re-infection. However, in the
62 COVID-19 patients, the re-infection is possible, whereas the definitive antibody level for protective
63 immunity remains inconclusive.^{4,5} Moreover, recent evidence suggests that a high neutralizing titer
64 may be required for protection against the circulating SAR-CoV-2 variants of concern (VOCs)
65 infection and symptomatic disease.^{6,7} To measure the SARS-CoV-2 vaccine-induced protective
66 immune response against the symptomatic infection, the neutralizing antibody titer against the SARS-
67 CoV-2 is a highly predictive indicator. The gold standard for neutralizing antibody detection is a
68 plaque reduction neutralizing test (PRNT₅₀), which requires live pathogen and complex laboratory
69 settings. Therefore, the more simplified technique using surrogate virus neutralization test (sVNT),
70 which detects total immunodominant neutralizing antibodies targeting the viral spike (S) protein
71 receptor-binding domain (RBD), is generally used as a high sensitivity and specificity rapid test.⁸
72 Additionally, the binding antibody (total antibodies including IgG, IgM, and IgA) against the SARS-
73 CoV-2 can be detected with simple laboratory techniques, including rapid test, Enzyme-Linked
74 Immunosorbent Assay (ELISA), and Electrochemiluminescence Assay.

75 Our study, therefore, aimed to determine the immune response after the SV and AZ
76 vaccination in the HCWs, in comparison with the patients recovered from the COVID-19 using sVNT
77 (%inhibition) and anti-SARS-CoV-2 total antibodies (U/ml). Moreover, the correlation between the
78 sVNT and anti-SARS-CoV-2 total antibodies for estimating vaccine efficacy against SARS-CoV-2
79 was evaluated.

80

81 **Methods (935 words)**

82 The prospective cohort study included HCWs who received the SARS-CoV2 vaccination at
83 King Chulalongkorn Memorial Hospital, Bangkok, Thailand. The study was approved by the Research
84 Ethics Review Committee, Faculty of Medicine, Chulalongkorn University, and was registered to the
85 Thai Clinical Trial (TCTR20210325003). The protocol was performed in accordance with the
86 declaration of Helsinki and its later amendments. All participants were voluntary to receiving the
87 SARS-CoV-2 vaccination and participating in the study with written informed consent.

88 ***Study Population***

89 Inclusion criteria were as follows: (1) HCWs aged 18 years old and above; and (2) no history
90 of the COVID-19. Patients who had (1) ongoing immunosuppressive medications; (2) any
91 vaccinations within 1 month; or (3) any blood components or intravenous immunoglobulin
92 administrations within 3 months; were excluded. Overall, each vaccination group consisted of 50
93 participants aged 18-40 years and 50 aged 41-70 years. In the SV group, 0.5 ml (3 µg) of inactivated
94 SARS-CoV-2 (CoronaVac®, Sinovac, or SV) vaccine was administered intramuscularly at the deltoid
95 region, using a 2-dose regimen with an interval of 21-28 days. For the ChAdOx1 nCoV-19
96 (Vaxzevria®, Oxford-AstraZeneca, or AZ) vaccination group, 0.5 ml of the AZ containing 5×10^{10}

97 viral particles was administered intramuscularly at the deltoid region, using a 2-dose regimen with an
98 interval of 8-10 weeks.

99 For the COVID-19 group, data were collected from patients diagnosed with the SARS-CoV-2
100 infection at the Emerging Infectious Diseases Clinical Center at King Chulalongkorn Memorial
101 hospital from March to April 2020, which, at that time, the wild-type SARS-CoV-2 was the main
102 circulating strain in Thailand. The COVID-19 was diagnosed by reverse transcriptase-polymerase
103 chain reaction (RT-PCR) of SARS-CoV-2 from the throat and nasopharyngeal swab samples. The
104 COVID-19 patients were classified according to the clinical severity into mild COVID-19 and
105 COVID-19 pneumonia.

106 ***Demographics and Clinical Data***

107 Baseline demographics and clinical data, including medical history, current medications used,
108 and a history of exposure to the COVID-19 patients, were collected. In addition, for the COVID-19
109 patients, the clinical characteristics of the SARS-CoV-2 infections were evaluated.

110 ***Sample Collections and Study Protocol***

111 For the vaccination groups, 4-ml clotted blood was collected at baseline for all participants,
112 then at 4 and 12 weeks (+/-2 weeks) after the second dose of the SV vaccination and at 4 weeks (+/-2
113 weeks) after the first and second doses of the AZ vaccination.

114 For the COVID-19 group, the blood samples were collected at the time of diagnosis and 4±2
115 weeks after diagnosis.

116 ***The Detection of Antibody Titers Against SARS-CoV-2***

117 The antibody titers against SARS-CoV-2 were determined by the surrogate neutralizing
118 antibody and total antibodies using the ELISA technique.

119 **1. The SARS-CoV-2 Neutralizing Antibody**

120 The SARS-CoV-2 neutralizing antibody was detected by the blocking ELISA technique of the
121 cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript), which the US Food and
122 Drug Administration (FDA) issued Emergency Use Authorizations (EUAs). The protein-protein
123 interaction between Horseradish peroxidase (HRP) conjugated recombinant SARS-CoV-2 RBD
124 fragment (HRP-RBD), and the human ACE2 receptor protein (hACE2) can be blocked by neutralizing
125 antibodies against SARS-CoV-2 RBD. The neutralizing antibody level was detected as percent signal
126 inhibition (%inhibition) following the manufacturer's protocol. Briefly, serum (negative or positive
127 controls) was diluted 10-fold in a sample diluent (as described in the package insert), mixed with
128 HRP-RBD, then incubated at 37°C for 30 minutes. After incubation, the mixture was added to the
129 hACE2-coated well and incubated at 37°C for 30 minutes. The ELISA plate was then washed with a
130 wash solution for 4 times. The 3,3',5,5'-tetramethylbenzidine (TMB) substrate was added and
131 incubated for 15 minutes. Finally, the stop solution was added before the optical density (OD) value at
132 450 nm was read. The antibody level is described as the percentage of signal inhibition or
133 %inhibition.⁸ The percent signal inhibition was calculated using the equation from the manufacturer
134 with the cut-off level for SARS-CoV-2 neutralizing antibody detection of $\geq 30\%$ inhibition.

$$135 \quad \text{Percent signal inhibition} = \left(1 - \frac{\text{OD value of sample}}{\text{OD value of negative control}} \right) \times 100\%$$

136 The seroconversion rate was defined as sVNT $\geq 68\%$, adopted from the USA-FDA guidance of
137 a high titer of the COVID-19 convalescent plasma.⁹

138 **2. The SARS-CoV-2 Total Antibodies**

139 The SARS-CoV-2 total antibodies were detected by the Elecsys® Anti-SARS-CoV-2 S using
140 Cobas e411 immunoassay analyzers (Roche Diagnostics, Rotkreuz, Switzerland), which is also the
141 US-FDA EUAs. The Elecsys® is the immunoassay for SARS-CoV-2 total antibodies against the RBD
142 of the S antigen detection, and the antibody level is reported as U/ml. Two hundred microliter of
143 serum sample was used following the manufacturer's protocol. The criteria of negative for anti-SARS-
144 CoV-2-S is <0.8 U/ml. For the participants who had the SARS-CoV-2 total antibodies over the
145 maximum measuring range (which is >250 U/ml), 10-fold diluted samples using the Elecsys® Diluent
146 Universal were re-evaluated. Moreover, the baseline serum of each participant in the vaccination
147 groups was confirmed to be negative for the SARS-CoV-2 total antibodies.¹⁰ The seroconversion rate
148 was defined as the anti-SARS-CoV-2 total antibodies ≥ 132 U/ml as suggested by the US-FDA of the
149 high titer for COVID-19 convalescent plasma.⁹

150 The level of anti-SARS-CoV-2 total antibodies (measured in U/ml) from the Elecsys® test was
151 converted to the BAU/ml following the first WHO International Standard for anti-SARS-CoV-2
152 immunoglobulin, which 1 U/ml is equivalent to 0.972 BAU/ml.¹¹

153 *Statistical Analysis*

154 Demographics and clinical and laboratory parameters were described in descriptive statistics.
155 Continuous variables were presented as median and interquartile range (IQR). The Wilcoxon rank-sum
156 test was applied to compare the continuous variables between two groups and the Kruskal-Wallis test
157 in case of more than two groups. The Chi-square test or Fisher exact test were used to compare the
158 proportion between groups. The correlation between sVNT and anti-SARS-CoV-2 total antibodies was
159 determined by the Spearman rank test. Statistical significance was considered as $P < 0.05$. STATA
160 version 15.1 (Stata Corp., College Station, Texas) was used for statistical analysis.

161 **Results**

162 For the vaccination groups, a total of 200 HCWs participated in the study. However, only 185
163 participants completed the 2-dose regimen of the vaccinations and had the blood collection at 1 month
164 after the second dose (94 and 91 participants in the SV and the AZ groups, respectively). The median
165 (IQR) intervals between the second dose and the blood collection were 23 (22-24) days for the SV
166 group and 19 (16-21) days for the AZ group. For the COVID-19 group, a total of 182 COVID-19
167 patients were admitted to King Chulalongkorn Memorial Hospital during March and April 2020. One
168 hundred eleven patients had convalescent sera collected at approximately 1 month after diagnosis with
169 a median (IQR) interval of 35 (30-38) days. Of 111 patients, 58 were diagnosed with mild COVID-19
170 (including upper respiratory tract infection (URI)) and 53 with COVID-19 pneumonia (including 26
171 moderate and 23 severe pneumonia (who required oxygen supplement or ventilator support) patients).
172 Demographic data and clinical characteristics are described in Table 1. At baseline, the immune
173 response of all participants in the vaccination groups was confirmed to be negative by both tests.

174 ***The SARS-CoV-2 Neutralizing Antibodies (sVNT, %inhibition)***

175 The sVNTs (%inhibition) at 4 weeks after completing the second dose of the vaccinations are
176 demonstrated in Table 2 and Figure 1. The median (IQR) of SARS-CoV-2 sVNT was 77.0 (58.5-87.9)
177 %inhibition in the SV group, 90.4 (75.2-96.2) %inhibition in the AZ group, 80.8 (61.5-92.1)
178 %inhibition in the mild COVID-19 group, and 94.5 (88.1-95.8) %inhibition in the COVID-19
179 pneumonia group.

180 For the SV group, sVNT tended to be lower in the older age group but was not statistically
181 significant (83.2%inhibition in the 20-30 years group vs 73.4%inhibition in the 51-60 years group,
182 P=0.18). There was no statistically significant difference of sVNT between age ranges and sexes in

183 each group. (Table 2) Comparing to the convalescent sera of the COVID-19 patients, the SV group
184 had a level of SARS-CoV-2 neutralizing antibodies comparable to the mild COVID-19 group. In
185 contrast, the AZ group had a higher level of neutralizing antibodies comparable to the COVID-19
186 pneumonia group. (Figure1)

187 At 12 weeks after the second dose of the SV vaccination, the median (IQR) of SARS-CoV-2
188 sVNT was 38.7 (22.1-55.7) %inhibition, which significantly decreased from the immune response at 4
189 weeks (77.0 (58.5-87.9) %inhibition) ($P<0.001$). (Figure 2A, Supplementary Table 1) On the contrary,
190 the median (IQR) of SARS-CoV-2 sVNT at 4 weeks after the first dose of AZ was 37.6 (6.5-63.2)
191 %inhibition and significantly increased after the second dose ($P<0.001$). (Figure 2B, Supplementary
192 Table 2)

193 For the US-FDA guidance of a high titer of the COVID-19 convalescent plasma, the
194 %inhibition using the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit should be 68%
195 and over (or $\geq 68\%$ inhibition). At 4 weeks after completing the vaccinations, 57/94 (60.6%)
196 participants in the SV group had $\geq 68\%$ inhibition, compared to 78/91 (85.7%) participants in the AZ
197 group. (Table 3) However, only 11/90 (12.2%) participants in the SV group had the high titers at 12
198 weeks after the second dose. (Supplementary Table 1). For the AZ group, 18/87 (20.7%) participants
199 had $\geq 68\%$ inhibition at 4 weeks after the first dose with the median (IQR) sVNT of 37.6 (6.5-63.2)
200 %inhibition. (Supplementary Table 2)

201 For sensitivity analysis, a higher cPass™ SARS-CoV-2 Neutralization Antibody Detection
202 Assays of $\geq 80\%$ inhibition was used as a surrogate marker for high sVNT against the SARS-CoV-2
203 variants of concerns. Consequently, only 43/94 (45.7%) participants in the SV group and 64/91
204 (70.3%) participants in the AZ group had $\geq 80\%$ inhibition, compared to 46/53 (86.8%) patients in the
205 COVID-19 pneumonia group ($P<0.001$). (Table3)

206 **The SARS-CoV-2 Total Antibodies**

207 The median (IQR) of anti-SARS-CoV-2 total antibodies were 188.6 (115.6-312.2) U/ml in the
208 SV group, 794.2 (497.9-1383.0) U/ml in the AZ group, 66.9 (19.7-170.2) U/ml in the mild COVID-19
209 group, and 794.2 (497.9-1383) U/ml in the COVID-19 pneumonia group. In the SV group, the anti-
210 SARS-CoV-2 total antibodies among the older age group tended to be decreased but were not
211 statistically significant (275.8 U/ml in the 20-30 years group vs 185.6 U/ml in the 51-60 years group,
212 P=0.28).

213 Using the US-FDA guidance of a high titer of the COVID-19 convalescent plasma, the cut-off
214 index (COI) for the ElecysTM test anti-SARS-CoV-2 total antibodies is ≥ 132 U/ml. Using the US-
215 FDA COI criteria, 67/94 (71.3%) participants in the SV group and 91/91(100%) participants in the AZ
216 group had seroconversion. (Table 3) Notably, the anti-SARS-CoV-2 total antibodies of the AZ group
217 were significantly higher than the COVID-19 pneumonia group (P<0.001). (Figure1)

218 According to the generalized additive models to estimate the immune marker values, in this
219 case, the anti-SARS-CoV-2 total antibodies using the ElecysTM kit technique (converted to BAU/ml),
220 the vaccine efficacy of SV and AZ were 50% and 70%, respectively.¹¹ (Supplementary Table 3, 4)

221 ***Correlation Between The SARS-CoV-2 Neutralizing Antibodies and The Anti-SARS-CoV-2 Total*** 222 ***Antibodies***

223 The Spearman correlation coefficient between the sVNT and the anti-SARS-CoV-2 total
224 antibodies was 0.79 for the SV group and 0.86 for the AZ group. (Figure 3) Interestingly, 78/91
225 (86.7%) participants in the AZ group had both high neutralizing antibodies (sVNT $\geq 68\%$ inhibition)
226 and high binding antibodies (anti-SARS-CoV-2 total antibodies ≥ 132 U/ml), compared to 55/94
227 (58.5%) participants in the SV group (P<0.001).

228 **Discussion**

229 This study presented the short-term immune response of Thai HCWs after completing the 2-
230 dose regimens of both the SV and AZ for one month and at three months after the SV vaccination. In
231 this study, the surrogate immune markers were used to predict the vaccine efficacy to protect against
232 the SARS-CoV-2 infection and/or symptomatic disease.

233 The immune response of the AZ group as measured by the sVNT was higher than the SV
234 group (85.7% vs 60.8%inhibition). Additionally, the binding antibodies, or the anti-SARS-CoV-2 total
235 antibodies, of ≥ 132 IU/ml was 100% in the AZ group and only 71% in the SV group. At 3-month after
236 completing the SV vaccination, sVNT significantly declined to 12.2%. Similarly, the rapid decline of
237 protective immunity was observed after the SARS-CoV-2 infection, as described by the progressive
238 decline of the sVNT after 5-8 weeks post-infection and the decreased systemic IgA antibody level at 8
239 weeks post-infection.¹²⁻¹³ In our study, HCWs who completed the 2-dose regimen of the SV
240 vaccination, demonstrated a rapid decrease of sVNT at 12 weeks afterwards, and the anti-SARS-CoV-
241 2 total antibodies were just equivalent to the mild COVID-19 patients. As the SARS-CoV-2
242 neutralizing antibodies level implicated the vaccine efficacy against the SARS-CoV-2 infection and
243 symptomatic disease, the rapid reduction of the sVNT should prompt the concerns of reduced vaccine
244 efficacy at 1-6 months after the complete SV vaccination. Moreover, the protective immunity against
245 the SARS-CoV-2 VOC tends to require a high sVNT, though the definitive level is inconclusive.
246 Thus, HCWS who previously received the SV vaccination should have a vaccine booster to accelerate
247 the sVNT level. In the AZ group, though the immune response was low after the first dose, then
248 dramatically increase after the second dose. Therefore, the interval period of the vaccination should be
249 shortened to accelerate the sVNT level to protect against the SARS-CoV-2 VOC earlier.

250 The study in Chile reported the vaccine effectiveness of the SV to be 65.9% for the prevention
251 of COVID-19.¹⁴ In our study, the seroconversion rate was an immune marker that implicated the
252 protective immunity against the SARS-CoV-2 infection. Therefore, the 60.8% seroconversion rate in
253 the SV group should be equivalent to the reported vaccine effectiveness from Chile. Notably, the study
254 in Chile was conducted during Feb-April 2021, when the circulating strains were Alpha (B.117) and
255 Gamma (P1). Furthermore, in the SV group, the immune response tended to decrease with age,
256 corresponding with the data from the phase 1/2 clinical trials of the SV in healthy adults aged 60 years
257 and older.¹⁵ This finding supports the Thai government initial policy of vaccine allocation, provide the
258 SV to younger age group (18-59 years) and the AZ to the elderly (≥ 60 years).

259 In the AZ group, a robust immune response was observed in all age groups, including the
260 elderly, corresponding with the phase 2/3 study of the ChAdOx1 nCoV-19 vaccine in young and old
261 adults.¹⁶ In addition, vaccine efficacy of the AZ was similar to the study in Brazil, South Africa, and
262 the UK.¹⁷ Of note, the level of the AZ-induced immune response was 4-time higher than the
263 convalescent sera after the wild-type SARS-CoV-2 infection. However, vaccine efficacy was expected
264 to be reduced for the SARS-CoV-2 VOC. In Thailand, B1.617.2 (Delta) variant has been the main
265 circulating SARS-CoV-2 VOC since July 2021. According to the study from the serum of the mRNA-
266 1273 (Spikevax®, Moderna) vaccinated patients, the neutralizing antibody titers against Delta was 2.9
267 times less susceptible to neutralization¹⁸; therefore, a booster vaccine may also require after the
268 complete AZ vaccination. The Com-Cov study also supported the new vaccine regimen of
269 heterogenous prime-boost COVID-19 vaccination using AZ prime and boost with mRNA-BNT162b2
270 (Comirnaty®, Pfizer–BioNTech).¹⁹

271 A single dose of AZ also demonstrated efficacy in reducing the disease severity. Regarding the
272 immunological mechanism of the AZ vaccine-induced protection against SARS-CoV-2, the low sVNT

273 level after the first dose of AZ may be explained by the sole measurement of humoral response mainly
274 from the B-cell activation. However, as a viral vector vaccine, the cellular responses (including the T
275 cells) were also activated but were under-estimated by the sVNTs. Thus, the AZ-induced Th1 and
276 CD8 T cell activity after the first dose of the AZ may contribute to the vaccine efficacy in ameliorating
277 the disease severity.^{3,20}

278 Moreover, a correlation coefficient between sVNT and anti-SARS-CoV-2 total antibodies were
279 higher in the AZ group (0.86) than the SV group (0.79). The lower correlation coefficient may be
280 explained by the different immunological mechanisms of the inactivated viral vaccine, including the
281 SV, which induces a lower neutralising antibody level. Consequently, though some individuals had
282 high titers of the SARS-CoV-2 total antibodies, the sVNT was low, indicating that the majority of
283 anti-SARS-CoV-2 total antibodies were not neutralizing antibodies. Although other non-neutralizing
284 antibodies might also contribute to the protective immunity,³ the neutralization level is highly
285 predictive of immune protection.²¹ Therefore, the anti-SARS-CoV-2 total antibodies following the SV
286 vaccination might not sufficiently represent the immune response against the SARS-CoV-2 infection,
287 using the more accessible laboratory technique.

288 There were several strengths of this study. Firstly, as the HCWs were the first group who
289 received the SARS-CoV-2 vaccinations in Thailand, our data will guide the policymakers of the Thai
290 National Vaccine Roll-Out Program to outline the vaccine programs for the country. Secondly, the
291 HCWs has an effective surveillance protocol to screen for the SAR-CoV-2 infection. Therefore, if no
292 episode of SARS-CoV-2 infection was documented, the immune response should solely result from
293 the vaccination.

294 This study has some limitations. Firstly, there were no definitive cut-off level of the sVNT and
295 the SARS-CoV-2 total antibodies for protection against both wild-type SARS-CoV-2 virus and the

296 SARS-CoV-2 VOC. Therefore, a high sVNT $\geq 68\%$ and 80% inhibition by the US-FDA were adopted
297 to implicate the protective immunity. Moreover, previous studies reported the high correlation
298 between the sVNT and the PRNT₅₀⁸ and the equivalent sVNTs of the convalescent sera of the severe
299 COVID-19 patients. Secondly, both sVNT and the SARS-CoV-2 total antibodies only represented the
300 humoral immune response. Further studies on the cellular immune responses after the vaccination are
301 ongoing, comparing the T-cell activities by the ELISpot assay between the individuals who received
302 the AZ and the SV vaccinations. Theoretically, the AZ vaccine, a viral vector vaccine platform, should
303 have a better cell-mediated immune response than the SV vaccine, an inactivated virus vaccine
304 platform.

305 In general, a highly effective vaccine with the lowest possible side effects should be offered to
306 the front-line HCWs. From our data, the HCWs who completed 2 doses of the SV vaccination should
307 be considered for a booster vaccine, and the HCWs who received the first dose of the AZ vaccination
308 should shorten the interval for the second dose.

309 **Conclusion**

310 During the COVID-19 pandemic, the HCWs are at very high risk, as they are the front-line
311 team to deal with the patients. Therefore, all protective measures, including non-pharmacological
312 (including personal protective equipment) and pharmacological (including a SARS-CoV-2
313 vaccination), should be highly regarded. Currently, high proportions of young HCWs in Thailand
314 completed the SV vaccinations. However, after completing the vaccination, the short-term immune
315 response appeared to be lower in the SV group than in the AZ group. Moreover, the HCWs in the SV
316 group experienced a rapid decline of the immune response as early as three months after the complete
317 vaccination. In this study, our results emphasized the urgent need for the booster vaccine for the

318 HCWs, particularly in the SV vaccination, in amidst the circulating SARS-CoV-2 VOC such as the
319 delta strain.

320 **Conflicts of Interest**

321 The authors declare that there is no conflict of interest regarding the publication of this article.

322 **Acknowledgements**

323 We would like to thank all health care workers at King Chulalongkorn Memorial Hospital (KCMH) as
324 well as the study team including Saithip khumpiwudum, Phattharasuda Yodbutdee and Thitima
325 maneepornpol. We also thank Susama Chokesuwattanaskul, of the Department of Ophthalmology,
326 Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, for help
327 with manuscript editing.

328 Funding: The Rachadaphiseksomphot Fund (RA(PO)002/64) from the Faculty of Medicine,
329 Chulalongkorn University and the King Chulalongkorn Memorial Hospital Fund for research (HA-64-
330 3300-21-024). NH was supported by the Ratchadaphiseksomphot Matching Fund from the Faculty of
331 Medicine, Chulalongkorn University. VR was supported by the Postdoctoral Fellowship Scholarships,
332 Ratchadapisek Somphot Fund, Chulalongkorn University. Part of this work was supported by the
333 Biobank, Faculty of Medicine, Chulalongkorn University.

334 **Author contributions**

335 TP, SW, NH, LP GP, and OP contributed substantially to the conception and design of this study. WJ,
336 NC, RP and PT contributed substantially to the acquisition of the data. WJ, NP, SW, VR, NH, TP and
337 JS analyzed and interpreted the data. WJ, NP, and TP drafted the manuscript. LP, GS, TP, SW, NH
338 and OP contributed substantially to the manuscript revision. All the authors approved the final version
339 submitted for publication and take responsibility for the statements made in the published article.

340 **Reference**

- 341 1. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and
342 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report
343 of a phase 1/2, single-blind, randomised controlled trial. *Lancet*. 2020;396:467-78.
- 344 2. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of
345 an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-
346 blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis*. 2021;21:181-92.
- 347 3. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced
348 protection against COVID-19 in humans. *Nat Rev Immunol*. 2021:1–10.
- 349 4. Wang J, Kaperak C, Sato T, Sakuraba. COVID-19 reinfection: a rapid systematic review of
350 case reports and case series. *J Investig Med*. 2021;69:1253-5.
- 351 5. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibody
352 Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J Med*.
353 2021;384:533-40.
- 354 6. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 vaccine
355 against the B.1.1.7 and B.1.351 variants. *N Engl J Med*. 2021;385:187-9.
- 356 7. Bernal JL, Andrew N, Gower C, Gallaher E, Simmons R, et al. Effectiveness of COvid-19
357 vaccines against the B.1.617.2 (delta) variant. *N Engl J Med*. 2021; Jul 21 doi:
358 10.1056/NEJMoa2108891. [Epub ahead of print].
- 359 8. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus
360 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein
361 interaction. *Nat Biotechnol*. 2020;38:1073-8.

- 362 9. De Santis GC, Mendrone A, Langhi D Jr, Covas DT, Fabron A Jr, Cortez AJP, et al. Suggested
363 guidelines for convalescent plasma therapy for the treatment of COVID-19. *Hematol Transfus*
364 *Cell Ther.* 2021;43:212-3.
- 365 10. Elecsys Anti-SARS-CoV-2. [cited 2021 Jul 16]. Available from:
366 <https://www.fda.gov/media/137605/download>
- 367 11. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against
368 symptomatic and asymptomatic SARS-CoV-2 infection. medRxiv 21258528 [Preprint]. 2021
369 [cited 2021 Jul 10]. Available from: <https://doi.org/10.1101/2021.06.21.21258528>
- 370 12. Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, et al. Rapid decline of
371 neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. *Nat*
372 *Commun.* 2021;12:844.
- 373 13. Dispinseri S, Secchi M, Pirillo MF, Tolazzi M, Borghi M, Brigatti C, et al. Neutralizing
374 antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for
375 survival. *Nat Commun.* 2021;12:2670.
- 376 14. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an
377 Inactivated SARS-CoV-2 Vaccine in Chile. *N Engl J Med.* 2021; Jul 7. doi:
378 10.1056/NEJMoa2107715. [Epub ahead of print].
- 379 15. Iversen PL, Bavari S. Inactivated COVID-19 vaccines to make a global impact. *Lancet Infect*
380 *Dis.* 2021;21:746-8.
- 381 16. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al.
382 Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost
383 regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3
384 trial. *Lancet.* 2021;396:1979-93.

- 385 17. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and
386 efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim
387 analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*.
388 2021;397:99-111.
- 389 18. Edara VV, Pinsky BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, et al. Infection and
390 Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. *N*
391 *Engl J Med*. 2021; Jul 7. doi: 10.1056/NEJMc2107799. [Epub ahead of print].
- 392 19. Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD, et al. Heterologous
393 prime-boost COVID-19 vaccination: initial reactogenicity data. *Lancet*. 2021;397:2043-6.
- 394 20. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. T cell
395 and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in
396 a phase 1/2 clinical trial. *Nat Med*. 2021;27:270-8.
- 397 21. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
398 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2
399 infection. *Nat Med*. 2021;27:1205-11.

Table 1: Demographics data of health care workers who received inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) and ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) or patients with COVID-19 diseases

	Inactivated	ChAdOx1	All COVID-19	COVID-19		P-value
	SARS-CoV2	nCoV-19	disease	mild COVID-19	COVID-19 pneumonia	
	(SV) (N=94)	(AZ) (N=91)	(N=111)	(N=58)	(N=53)	
Age, year, median (IQR)	40.8 (30.8-51.4)	40.4 (29.6-60.4)	36 (27-47)	31 (26-38)	43 (32.5-50.5)	0.001 ^a
Age group, n (%)						<0.001 ^b
• 20-30 year	26 (27.7)	30 (33)	40 (36)	28 (48.3)	12 (22.6)	
• 31-50 year	44 (46.8)	19 (20.9)	54 (48.7)	27 (46.7)	27 (50.9)	
• 51-70 year	24 (25.5)	42 (46.2)	17 (15.3)	3 (5.2)	14 (26.4)	
Female, n (%)	76 (80.9)	68 (72.3)	67 (60.4)	37 (63.8)	30 (57.7)	0.005 ^b
BMI (kg/m ²), median (IQR)	22 (20.1-25.6)	22.8 (20.3-25.6)	22.5 (19.5-26.7)*	20.8 (18.8-23.2)	23.4 (19.8-27.1)	0.45 ^a

Interval between vaccine completion or COVID-19 diagnosis and the blood collection, day, median (IQR)	23 (22-24)	19 (16-21)	35 (30-38)	34 (30-38)	35 (31-39)	NA
--	------------	------------	------------	------------	------------	----

*N=55

a indicates P-value from Kruskal-Wallis test and b from Chi-square test

Abbreviations: IQR=interquartile range

Table 2: Median (IQR) of the SARS-CoV2 Neutralizing antibody using the cPass™ test and the anti-SARS-CoV-2 total antibody using the Elecys™ test at 4 weeks after complete 2-dose of inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) and ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) compare to convalescent sera after COVID-19 disease

Median (IQR)	SARS-CoV2 Neutralizing antibody (%inhibition)					Anti-SARS-CoV-2 total antibody (U/mL)				
	Inactivated SARS-CoV2 (SV) (N=94)	ChAdOx1 nCoV-19 (AZ) (N=91)	mild COVID-19 (N=58)	COVID-19 pneumonia (N=53)	P-value ^a	Inactivated SARS-CoV2 (SV) (N=94)	ChAdOx1 nCoV-19 (AZ) (N=91)	mild COVID-19 (N=58)	COVID-19 pneumonia (N=53)	P-value ^a
Overall	77.0 (58.5-87.9)	90.4 (75.2-96.2)	80.8 (61.5-92.1)	94.5 (88.1-95.8)	<0.001	188.6 (115.6-312.2)	794.2 (497.9-1383.0)	66.9 (19.7-170.2)	241.3 (170.3-442.9)	<0.001
Age, year										
20-30	83.2 (59.0-92.7)	88.2 (78.1-95.9)	74.7 (52.9-89.9)	91 (76.2-94.5)	0.03	275.8 (101.1-580.2)	583.1 (459.7-864.7)	49.2 (14.9-119.9)	183.1 (81-244.2)	<0.001
31-50	77.3 (59.1-87.5)	95.6 (75.6-97.9)	89.5 (64-94.3)	94.7 (89.8-95.7)	<0.001	187.6 (115.6-282.3)	933.6 (516.2-1949)	125.9 (18.1-192.1)	241.3 (181.1-495.8)	<0.001
51-70	73.4	90.2	84.7	95.7	<0.001	185.6	841.2	39.9	376.8	0.001

	(49.3-83.2)	(72.5-95.6)	(71.3-92.1)	(93.8-96.8)		(129.9-286.3)	(497.9-1657)	(21.9-226.1)	(207.9-936.4)	
P-value^a	0.11	0.27	0.39	0.04		0.22	0.09	0.32	0.04	
<hr/>										
Sex										
Male	67.9	85.4	71.3	95.3	<0.001	180.1	735.4	40.8	411.1	<0.001
	(58.5-86.2)	(74.0-93.8)	(53.5-89.4)	(91.8-96.1)		(101.1-227.1)	(447.6-886.4)	(5.42-108.7)	(241.3-866.9)	
Female	78.6	91.1	84.6	93.8	<0.001	222.5	834.1	107.5	208.1	<0.001
	(57.0-88.5)	(75.2-96.9)	(72.1-92.7)	(87.7-95.6)		(120.5-339.1)	(506.9-1506)	(21.8-192.1)	(142.7-354.6)	
P-value^b	0.59	0.16	0.10	0.13		0.42	0.18	0.15	0.01	

a indicates P-value from Kruskal-Wallis test and b from Wilcoxon rank sum test

Table 3: The seroconversion rates of health care workers who received inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) and ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) and patients with COVID-19 infection who achieved the SARS-CoV2 neutralizing antibody $\geq 68\%$ inhibition and $\geq 80\%$ inhibition and anti-SARS-CoV-2 total antibody of ≥ 132 U/mL

Seroconversion rate	Inactivated SARS-CoV2 (SV) (N=94)	ChAdOx1 nCoV-19 (AZ) (N=91)	Mild COVID-19 (N=58)	COVID-19 Pneumonia (N=53)	P-value
%Inhibition $\geq 68\%$ (N, (%))	57 (60.6)	78 (85.7)	40 (69)	49 (92.5)	<0.001
%Inhibition $\geq 80\%$ (N, (%))	43 (45.7)	64 (70.3)	30 (51.7)	46 (86.8)	<0.001
SARS-CoV-2 total antibody ≥ 132 U/mL (N, (%))	67 (71.3)	91 (100)	20 (34.5)	44 (83)	<0.001
P-value from Chi-square test					




Figure 1: A. the SARS-CoV-2 Neutralizing antibody using the cPassTM test (% inhibition) B. the anti-SARS-CoV-2 total antibody using the ElecysTM test (U/mL) after complete 2-dose of inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) and ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) compare to convalescent sera after COVID-19 diseases




Figure 2: A. The kinetic of the SARS-CoV-2 Neutralizing antibody using the cPassTM test (% inhibition) in health care workers who received inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) at 4 and 12 weeks after complete 2-dose immunization. B. in health care workers who received ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) at 4 weeks after the first and the second dose of immunization




Figure 3: Correlation between the SARS-CoV-2 neutralizing antibody using the cPass™ test (% inhibition) and the anti-SARS-CoV-2 total antibody using the Elecsys™ test (U/mL) in health care workers who received inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) (A) and ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) (B) vaccination.

Supplement Table 1. The median (IQR) of the SARS-CoV-2 neutralizing antibody using the cPass™ test (% inhibition) in health care workers who received inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) at 4-week and 12-week after complete immunization.

SARS-CoV-2 Neutralizing antibody using the cPass™ test (%inhibition)			
Median, (IQR)	Weeks 4	Weeks 12	P-value^a
	N=94	N=90	
Overall	77.0 (58.5-87.9)	38.7 (22.1-55.7)	<0.001
Age, year			
20-30	83.2 (59.0-92.7)	40 (31.7-66)	<0.001
31-50	77.3 (59.1-87.5)	43.7 (21.2-57.4)	<0.001
51-70	73.4 (49.3-83.2)	32.4(15.3-43.3)	<0.001
P-value^b	0.11	0.06	
Sex			
Male	67.9 (58.5-86.2)	37 (15.1-58.3)	0.006
Female	78.6 (57.0-88.5)	38.8 (27.6-55.8)	<0.001
P-value^c	0.59	0.85	

a indicates P-value from Wilcoxon sign rank test, b from Kruskal-Wallis test and c from Wilcoxon rank sum test

Supplement Table 2. The median (IQR) of the SARS-CoV-2 neutralizing antibody using the cPass™ test (% inhibition) in health care workers who received ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) at 4-week and 12-week after the 1st and 2nd dose immunization.

SARS-CoV-2 Neutralizing antibody using the cPass™ test (%inhibition)			
Median, (IQR)	After 1st dose immunization	After 2nd dose immunization	P-value^a
	N=87	N=87	
Overall	37.6 (6.5-63.2)	90.4 (74.7-96)	<0.001
Age			
20-30 year	43.2 (29.9-72)	88.2 (76.6-95.8)	<0.001
31-50 year	56.1 (24.5-74.2)	95.8 (75.6-97.9)	<0.001
51-70 year	15 (0-44.4)	90.2 (72.5-95.3)	<0.001
P-value^b	0.002	0.18	
Sex			
Male	35.5 (1.7-51.9)	85.4 (72.5-93.6)	<0.001
Female	38.6 (13-68.9)	91.1 (75.2-96.7)	<0.001
P-value^c	0.38	0.13	

a indicates P-value from Wilcoxon sign rank test, b from Kruskal-Wallis test and c from Wilcoxon rank sum test

Supplementary Table 3: Median (IQR) of the anti-SARS-CoV-2 total antibody (BAU/mL) using the Elecys™ test at 4 weeks after complete 2-dose of inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) and ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) compare to convalescent sera after COVID-19 disease

Median (IQR)	Anti-SARS-CoV-2 Total antibody titer (BAU/mL)				P-value
	Inactivated SARS-CoV2 (SV) (N=94)	ChAdOx1 nCoV-19 (AZ) (N=91)	mild COVID-19 (N=58)	COVID-19 Pneumonia (N=53)	
Overall	194 (118.9-321.2)	817.1 (512.2-1422.8)	68.9 (20.2-175.1)	248.3 (175.2-454.6)	<0.001
Age, year					
20-30	283.7 (104-596.9)	599.8 (472.9-889.6)	50.6 (15.3-123.4)	188.4 (83.3-251.2)	<0.001
31-50	193 (118.9-290.4)	960.5 (531.1-2005.1)	129.5 (18.6-197.6)	248.3 (186.3-510.1)	<0.001
51-70	190.9 (133.6-294.5)	865.4 (512.2-1704.7)	41.1 (22.5-232.6)	387.7 (213.9-963.4)	<0.001
P-value	0.22	0.09	0.32	0.04	
Sex					
Male	185.2 (104-233.6)	756.5 (460.5-911.9)	41.9 (5.6-111.8)	422.9 (248.3-891.9)	<0.001

Female	228.9 (124-348.9)	858.1 (521.5-1549.4)	110.6 (22.4-197.6)	214.1 (146.8-364.8)	<0.001
P-value	0.42	0.18	0.15	0.01	


a indicates P-value from Kruskal-Wallis test and b from Wilcoxon rank sum test

Remarks: The level of anti-SARS-CoV-2 total antibody (measured in U/mL) from the Elecsys® test was converted to the BAU/mL following the first WHO International Standard for anti-SARS-CoV-2 immunoglobulin, which 1 U/ml is equivalent to 0.972 BAU/ml.¹¹


Supplementary Table 4: Vaccine efficacy according to the generalized additive models with immune marker values, which is anti-SARS-CoV-2 total antibody (BAU/mL) using the Elecys™ kit technique⁹ in health care workers after complete 2-dose of inactivated SARS-CoV-2 vaccine (CoronaVac®, Sinovac, or SV) and ChAdOx1 nCoV-19 vaccine (Vaxzevria®, Oxford-AstraZeneca, or AZ) compare to compare to convalescent sera after COVID-19 disease

Vaccine Efficacy	Anti-SARS-CoV-2 total antibody (BAU/mL)				P-value
	Inactivated SARS-CoV2 (SV) (N=94)	ChAdOx1 nCoV-19 (AZ) (N=91)	mild COVID-19 (N=58)	COVID-19 pneumonia (N=53)	
50% (≥18 BAU/mL)	94 (100)	91 (100)	45 (77.6)	53 (100)	<0.001
60% (≥50 BAU/mL)	88 (93.6)	91 (100)	31 (53.5)	50 (94.3)	<0.001
70% (≥165 BAU/mL)	58 (61.7)	91 (100)	17 (29.3)	41 (77.4)	<0.001
80% (≥506 BAU/mL)	13 (13.8)	69 (75.8)	0	11 (20.8)	<0.001
90% (≥2360 BAU/mL)	0	7 (7.7)	0	0	0.001


B




A



B




A



A

Spearman rank correlation=0.79; $P < 0.001$



B

Spearman rank correlation=0.86 ; $P < 0.001$

